Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A case of isolated unilateral renal mucormycosis post COVID-19 pneumonia with fatal outcome

Rajiv Kumar Sethia, Aakib Hamid Charag

PII: S2214-4420(22)00073-0
DOI: https://doi.org/10.1016/j.eucr.2022.102061
Reference: EUCR 102061

To appear in: Urology Case Reports

Received Date: 27 February 2022
Revised Date: 20 March 2022
Accepted Date: 23 March 2022

Please cite this article as: Sethia RK, Charag AH, A case of isolated unilateral renal mucormycosis post COVID-19 pneumonia with fatal outcome, Urology Case Reports (2022), doi: https://doi.org/10.1016/j.eucr.2022.102061.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc.
A CASE OF ISOLATED UNILATERAL RENAL MUCORMYCOSIS POST COVID-19 PNEUMONIA WITH FATAL OUTCOME

Rajiv Kumar Sethia 1, Aakib Hamid Charag 2

1. Associate Director and HOD, Urology and Kidney Transplant, Asian Institute of Medical Sciences, Faridabad, Haryana, India
2. Consultant, Urology and Kidney Transplant, Asian Institute of Medical Sciences, Faridabad, Haryana, India

Corresponding Author:
Aakib Hamid Charag 2
Department of Urology and Kidney Transplant
Asian Institute of Medical Sciences
Sector 21A, Badkhal Flyover Road, Faridabad, Haryana
Pin code – 121001
India
A CASE OF ISOLATED UNILATERAL RENAL MUCORMYCOSIS POST COVID-19 PNEUMONIA WITH FATAL OUTCOME

KEY WORDS
Pyelonephritis, emphysematous, COVID-19, mucormycosis

ABSTRACT
Mucormycosis is a rare disease. It is typically seen in immunocompromised patients. Isolated renal mucormycosis is an extremely rare disease. We here report a case of isolated renal mucormycosis who had recently recovered from COVID-19 pneumonia. The patient was a known case of diabetes mellitus and had already developed acute kidney injury when he reported to us. Despite aggressive medical and surgical management, the patient succumbed to the disease.
INTRODUCTION

There has been an exponential increase in the rhinocerebral mucormycosis in India after second Covid-19 wave. Isolated renal mucormycosis is rare and has not been reported as a complication of Covid-19 disease. Our case developed isolated unilateral emphysematous pyelonephritis and renal mucormycosis after recovery from Covid-19 pneumonia.

CASE REPORT

A 46-year-old male patient had developed COVID-19 pneumonia two months back for which he was treated elsewhere with steroids and other supportive medications. Patient was a known case of diabetes and hypertension from last 15 years. One month after his recovery from COVID-19 pneumonia, patient developed persistent fever and left flank pain. He was diagnosed as a case of Class 3B Left Emphysematous Pyelonephritis (Fig 1). His serum creatinine level was within normal limits. He was initially managed with broad spectrum antibiotics. Left DJ stenting and ultrasound guided drainage of perinephric collection was done with drain kept in situ.

He presented to our hospital two weeks after the placement of DJ stent and drain. He was still having fever episodes and left flank discomfort. His urine output had decreased over the past few days. On evaluation, he looked dehydrated and had facial puffiness. He had left ventricular dysfunction (LVEF – 40%). His blood glucose levels were in the range of 200-350mg/dl, hemoglobin was 10.1mg/dl and his serum creatinine level was 2.4mg/dl. We did not obtain any specific serum fungal culture since we were not suspecting any fungal infection at the outset. Routine bacterial blood and urine culture at our hospital did not reveal any fungal growth.

After initial stabilization this patient was planned for Left Nephrectomy after discussing the procedure and anticipated complications with the family. Before surgery, patient underwent SLED (sustained low efficiency dialysis) as per nephrologist’s advice in view of hyperkalemia and deranged arterial blood gas analysis. Procedure was initially attempted laparoscopically. However, in view of dense
inflammation around the kidney, conversion to open surgery was done. Left subcostal incision was made and nephrectomy was completed. Large bowel could be dissected off the kidney. Left kidney was necrotic with multiple pockets of purulent fluid around the kidney. Perirenal fascia appeared thickened. Hilar vessels were encased in inflammatory tissue. Kidney was densely adherent to the posterolateral abdominal wall. A 28Fr abdominal tube drain was placed before the closure of incision. Towards the end of surgery, patient developed hypotension and metabolic acidosis. The blood loss was about 600ml. Despite blood transfusion, vasopressors and therapy for metabolic acidosis, patient could not be extubated. Patient was shifted to ICU and put on ventilatory support. During the postoperative period, patient was managed with ventilatory support, antibiotics and other supportive care. In view of oliguria and persistent metabolic acidosis, nephrology consultation was done. Hemodialysis was done as per nephrologist’s advice. Histopathology report of the nephrectomy specimen showed mucormycosis. Broad PAS positive hyphae (5 to 15 micron diameter), irregularly branched with rare septations (Fig 2) and extensive necrosis (Fig 3) were seen in the kidney. Liposomal Amphotericin B was started as per the intensivist advice on fourth post operative day. On fifth postoperative day, patient developed sudden bradycardia for which resuscitation was done but patient developed cardiopulmonary arrest and could not be reviewed.

DISCUSSION

Mucormycosis is rare in healthy immunocompetent individuals. However, the use of steroids for the management of Covid-19 disease has increased the risk of opportunistic infections especially in diabetic patients. Several cases of post Covid-19 mucormycosis involving different organs have been reported in literature. In August 2021, Singh AK et al [1] have presented a systematic review of post covid-19 mucormycosis cases reported in literature. As per the study, 101 cases of mucormycosis in people with COVID-19 were reported which included predominantly male patients (78.9%).
Selarka L et al [2] reported that out of 2567 COVID-19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycosis. Most were not COVID-19 vaccinated and had developed moderate-to-severe pneumonia. All patients had received corticosteroids and broad-spectrum antibiotics while most \((n = 37, 78.7\%)\) received at least one anti-viral medication. Mean time elapsed from COVID-19 diagnosis to mucormycosis was \(12.1 \pm 4.6\) days. Eleven (23.4\%) subjects succumbed to their disease, mostly \((n = 8, 72.7\%)\) within 7 days of diagnosis. Among the patients who died, 10 (90.9\%) had pre-existing diabetes mellitus.

Rhinocerebral involvement is the most common form of mucormycosis. Less commonly involved organs include lung, skin or gastrointestinal system. Renal mucormycosis is an extremely rare disease. Bilateral renal mucormycosis is nearly 100\% fatal especially in patients with acute kidney injury. [3]

A thorough review of literature revealed that till date none of the cases of “post COVID isolated renal mucormycosis” has been reported. Choudhary GR et al [4] has reported a case mucormycosis in a young male following recovery from COVID-19. This patient had simultaneous renal and bowel involvement. This patient was initially managed conservatively. Subsequently he underwent left-sided nephrectomy via the retroperitoneal incision. Intra-operatively, bowel appeared ischemic and congested for which an exploratory laparotomy was performed and gangrenous segment of the bowel beginning from the third part of duodenum till proximal jejunum was resected. This patient developed severe metabolic acidosis, septic shock with anuria and succumbed to his illness after 10 hours. We also had a multi-disciplinary team approach for the management of our patient both in the preoperative and post operative period. Despite our best efforts we could not save the patient. Our patient had poorly controlled diabetes and already had acute kidney injury when he reported to our centre.

We believe that an immediate and proactive treatment would have changed the situation. Early nephrectomy should have been done since there was no improvement after placing DJ stent and drain. In fact, the condition of the patient was still deteriorating and he developed
acute kidney injury. Early nephrectomy before acute kidney injury developed would have probably changed the outcome. Development of acute kidney injury is a bad prognostic factor in Emphysematous Pyelonephritis [5] and is associated with fatal outcome in Renal Mucormycosis.

CONCLUSION

Isolated renal mucormycosis can be fatal. High index of suspicion should be there to make the diagnosis. Early detection and aggressive management may have a favourable outcome.

REFERENCES

1. Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021). Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. *Diabetes & metabolic syndrome, 15*(4), 102146. https://doi.org/10.1016/j.dsx.2021.05.019

2. Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. *Mycoses*. 2021; 64: 1253–1260. https://doi.org/10.1111/myc.13353

3. L Gupta K, Gupta A. Mucormycosis and acute kidney injury. *J Nephropathol*. 2012;1(3):155-159. doi:10.5812/nephropathol.8111

4. Choudhary GR, Aggarwal A, Jain V, Jena R. COVID-19 and fatal renal mucormycosis: Contributory or coincidental?. *Indian J Urol*. 2021;37(3):270-273. doi:10.4103/iju.iju_197_21

5. Kapoor R, Muruganandham K, Gulia AK, Singla M, Agrawal S, Mandhani A, Ansari MS, Srivastava A. Predictive factors for mortality and need for nephrectomy in patients with
emphysematous pyelonephritis. BJU Int. 2010 Apr;105(7):986-9. doi: 10.1111/j.1464-410X.2009.08930.x. Epub 2009 Nov 20. PMID: 19930181.

LEGEND FOR FIGURES

Fig 1: Computed tomography images showing left emphysematous pyelonephritis

Fig 2: Broad based hyphae seen on microscopy

Fig 3: Extensive necrosis seen in kidney

KEY WORDS

Pyelonephritis, emphysematous, COVID-19, mucormycosis
